Open AccessFactors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program
Author(s) -
TzeFan Chao,
KeunSik Hong,
ByungChul Lee,
Raffaele De Caterina,
Paulus Kirchhof,
Paul-Egbert Reimitz,
Cathy Chen,
Martin Unverdorben,
ChunChieh Wang
Publication year - 2021
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000516
Subject(s) - medicine , edoxaban , dosing , atrial fibrillation , stroke (engine) , dose , observational study , medical prescription , demographics , emergency medicine , warfarin , dabigatran , pharmacology , mechanical engineering , demography , sociology , engineering
Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists as the standard of care for stroke prevention in patients with atrial fibrillation (AF). However, DOAC prescriptions at dosages that do not adhere to labeling are common in daily practice. This analysis from the observational Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program focuses on edoxaban-treated patients from South Korea and Taiwan to identify patient baseline characteristics that may be associated with non-recommended dosing.